These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 36334653

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J.
    Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation.
    Kong X, Xu Z, Wu Y, Tang X, Xue S, Miao M, Han Y, Wang Y, Chen S, Sun A, Qiu H, Wu D, Zhao Y, Chen F.
    J Hematol Oncol; 2024 Oct 12; 17(1):94. PubMed ID: 39396017
    [Abstract] [Full Text] [Related]

  • 25. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T, Kawano N, Yamashita K, Ueda A.
    J Clin Exp Hematop; 2014 Oct 12; 54(2):149-53. PubMed ID: 25318948
    [Abstract] [Full Text] [Related]

  • 26. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.
    Mensen A, Na IK, Häfer R, Meerbach A, Schlecht M, Pietschmann ML, Gruhn B.
    J Cancer Res Clin Oncol; 2014 Nov 12; 140(11):1971-80. PubMed ID: 24962343
    [Abstract] [Full Text] [Related]

  • 27. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM, Zheng XL, Zhu L, Ding L, Han DM, Liu J, Xue M, Li S, Wang HX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug 12; 30(4):1224-1229. PubMed ID: 35981389
    [Abstract] [Full Text] [Related]

  • 28. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S.
    Lancet Oncol; 2024 Mar 12; 25(3):376-387. PubMed ID: 38309282
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.
    Stocker N, Labopin M, Boussen I, Paccoud O, Bonnin A, Malard F, Amiel C, Gozlan J, Battipaglia G, Duléry R, Giannotti F, Ruggeri A, Gaugler B, Mohty M, Brissot E.
    Bone Marrow Transplant; 2020 Mar 12; 55(3):586-594. PubMed ID: 31562397
    [Abstract] [Full Text] [Related]

  • 31. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 12; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.
    Blood; 2002 Jun 15; 99(12):4364-9. PubMed ID: 12036863
    [Abstract] [Full Text] [Related]

  • 34. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ.
    Biol Blood Marrow Transplant; 2015 Dec 15; 21(12):2185-2191. PubMed ID: 26253005
    [Abstract] [Full Text] [Related]

  • 35. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis.
    Salas MQ, Prem S, Remberger M, Lam W, Kim DDH, Michelis FV, Al-Shaibani Z, Gerbitz A, Lipton JH, Viswabandya A, Kumar R, Kumar D, Mattsson J, Law AD.
    Leuk Lymphoma; 2020 Dec 15; 61(13):3198-3208. PubMed ID: 32715815
    [Abstract] [Full Text] [Related]

  • 36. [Clinical Analysis of Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation].
    Liu LX, Wang J, Wang L, Liu L, Wang X, Zhang HB, Tang XQ, Xiong YY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug 15; 32(4):1217-1223. PubMed ID: 39192423
    [Abstract] [Full Text] [Related]

  • 37. Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.
    Wang H, Zhang TT, Qi JQ, Chu TT, Miao M, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP, Han Y.
    Ann Hematol; 2019 Apr 15; 98(4):987-996. PubMed ID: 30715567
    [Abstract] [Full Text] [Related]

  • 38. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
    Reddy N, Rezvani K, Barrett AJ, Savani BN.
    Biol Blood Marrow Transplant; 2011 May 15; 17(5):591-7. PubMed ID: 20732435
    [Abstract] [Full Text] [Related]

  • 39. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.
    Transpl Infect Dis; 2019 Oct 15; 21(5):e13145. PubMed ID: 31301099
    [Abstract] [Full Text] [Related]

  • 40. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT, Xu LP, Liu DH, Liu KY, Zhang XH, Chen H, Chen YH, Han W, Wang FR, Wang Y, Wang JZ, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug 15; 34(8):651-4. PubMed ID: 23978013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.